← All indications
Psychomotor Agitation
A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.
Subtype terms (1)
More specific conditions that are subtypes of Psychomotor Agitation in the MeSH hierarchy.
- Akathisia, Drug-Induced
3 drugs (2 approved, 1 experimental)
Drugs by status
Approved for this indication (6)
Phase 4 trials (14)
Phase 2 trials (2)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (90)
- Abbott
- XenoPort, Inc.
- Forest Laboratories
- Astellas
- Schering-Plough
- Pfizer
- GlaxoSmithKline
- Neurocare
- Vifor Inc.
- Boehringer Ingelheim
- National Institute of Mental Health (NIMH)
- National Institute on Aging (NIA)
- United States Navy
- Huazhong University of Science and Technology
- Beijing HuiLongGuan Hospital
- Abarbanel Mental Health Center
- Ajou University
- University of Arizona
- Central South University
- Ain Shams University
- Augusta University
- Cairo University
- University of London
- Cleveland Sleep Research Center
- Cukurova University
- Harvard University
- Emory University
- Gelderse Vallei Hospital
- Guangzhou Medical University
- Hoosier Cancer Research Network
- +60 more
Organization Involved with Phase 3 Indications (43)
- Daiichi Sankyo
- UCB
- AstraZeneca
- Avanir
- Alexza Pharmaceuticals, Inc.
- Axsome Therapeutics, Inc.
- Axxonis Pharma AG
- Cognitive Research Corporation
- Shahid Beheshti University of Medical Sciences
- University of Pennsylvania
- University of Pittsburgh
- East Tennessee State University
- Johns Hopkins University
- McMaster University
- St. Luke's-Roosevelt Hospital Center
- Sykehuset Innlandet HF
- Tuscaloosa Research & Education Advancement Corporation (TREAC)
- University of Southern California
- University of Tehran
- University of Toronto
- University of Bergen
- University of Brasilia
- University of Virginia
- Medical University of South Carolina
- University of Strasbourg
- National Taiwan University
- Lee's Pharmaceutical
- Intra-Cellular Therapies
- Instituto de Medicina Integral Professor Fernando Figueira
- YuLi Hospital
- +13 more
Organization Involved with Phase 2 Indications (40)
- Schwarz Pharma
- Acadia Pharmaceuticals
- Ligand Pharmaceuticals
- Impax Laboratories
- Merck
- Elan Pharmaceuticals
- Ipsen
- Bioprojet
- Kyowa Hakko Kirin
- Merz
- Mediti Pharma Inc.
- Neurogen Corporation
- Pharmacosmos
- Bionomics Limited
- Transition Therapeutics
- National Institutes of Health (NIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Warner Chilcott
- Eastern Virginia Medical School
- Sleep Health Centers
- Universidad Autonoma de Madrid
- University of Melbourne
- University of Alberta
- University of Bordeaux
- Yale University
- Austin Health
- Old Dominion University
- The Alfred Hospital
- University of Minnesota
- Kyowa Kirin
- +10 more
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (32)
- Child Psychopharmacology Institute
- Heidi Moretti, MS, RD
- Al Jedaani Hospital
- Alexandria University
- University of Washington
- Inje University
- Makassed General Hospital
- Mansoura University
- Lowcountry Infectious Diseases
- Pamukkale University
- Rutgers University
- Seton Healthcare Family
- Thomas Jefferson University
- University of Medicine and Dentistry of New Jersey
- Yonsei University
- Catholic Health East
- Dalhousie University
- Fudan University
- Prince of Songkla University
- University of California, San Diego
- University of Central Florida
- Zhejiang University
- University of Indonesia
- University of Missouri
- Mercy Catholic Medical Center
- Yeungnam University
- OSF HealthCare
- Government of Canada
- Nintendo
- Lumbini Medical College
- +2 more